Close Menu

NEW YORK (GenomeWeb) – Exact Sciences reported after the close of the market on Thursday that its fourth quarter revenues rose 64 percent year over year, thanks to a 66 percent increase in the number of completed Cologuard colorectal cancer tests during the quarter.

For the three months ended Dec. 31, 2018, the Madison, Wisconsin-based molecular diagnostics company reported revenues of $143.0 million for Q4, up from $87.4 million in Q4 2017, and beating the average Wall Street estimate of $134.8 million.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.